FORMA THERAPEUTICS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2007-01-01
- Employees
- 101
- Market Cap
- -
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06198712
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
🇰🇪Kombewa Clinical Research Centre, Kisumu, Kenya
🇰🇪KEMRI-Walter-Reed Kericho, Kericho, Kenya
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT05953584
- Locations
- 🇮🇳
All India Institute of Medical Sciences (AIIMS), Raipur, Raipur, Chhattisgarh, India
🇮🇳All India Institute of Medical Sciences-Delhi, Delhi, India
🇮🇳Nirmal Hospital Pvt. Ltd., Gujarat, India
Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05725902
- Locations
- 🇺🇸
Emory University Children's Healthcare of Atlanta, Atlanta, Georgia, United States
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
- Conditions
- Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05568225
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Plainsboro, New Jersey, United States
🇺🇸Northwell Health, Plainsboro, New Jersey, United States
🇺🇸Northwestern Memorial Hospital, Plainsboro, New Jersey, United States
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
- Conditions
- Sickle Cell DiseaseThalassemia
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04987489
- Locations
- 🇺🇸
[Legal] Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸UCSF Oakland Benioff ChildHosp, Oakland, California, United States
🇺🇸[Legal] Children's Hospital of Orange County on behalf of CHOC Children's Hospital of Orange County, Orange, California, United States
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
- Conditions
- Sickle Cell Disease
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT04624659
- Locations
- 🇫🇷
Hospices Civils de Lyon-Hopital Edouard Herriot, Lyon, France
🇩🇪Univertatsklinikum Frankfurt, Frankfurt, Germany
🇪🇸Hospital Clínico San Carlos, Madrid, Spain
A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis
- Conditions
- Nonalcoholic Steatohepatitis (NASH)Overweight or Obesity
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04004325
- Locations
- 🇺🇸
ProSciento, Inc., Chula Vista, California, United States
🇺🇸Catalina Research Institute, Montclair, California, United States
A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients
- Conditions
- Healthy VolunteersSickle Cell Disease
- Interventions
- Drug: FT-4202/Placebo
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT03815695
- Locations
- 🇺🇸
Pacific Research Partners (SCD subjects only), Oakland, California, United States
🇺🇸St. Jude Children's Research Hospital (SCD subjects only), Memphis, Tennessee, United States
🇺🇸Children's Healthcare of Atlanta (SCD subjects only), Atlanta, Georgia, United States
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
- Conditions
- Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)Cohort 3a and 3b: ChondrosarcomaCohort 4a and 4b: Intrahepatic CholangiocarcinomaCohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT03684811
- Locations
- 🇺🇸
Banner MD Anderson, Gilbert, Arizona, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 336
- Registration Number
- NCT02719574
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇦🇺Box Hill Hospital, Monash University and Eastern Health Clinical School, Box Hill, Australia